Beckman Coulter

New biomarker to improve patient care

Becton Dickinson Holdings Pte. Ltd. Taiwan Branch

Laboratory Automation Total Solution

Bio Preventive Medicine Corp.

Bio Preventive Medicine Corp. (BPM) is a clinical staged biotech company focusing on development of novel biomarker based preventive diagnostic solutions for unmet clinical needs, especially chronic kidney disease and cancer. As leading company in renal biomarker area, BPM’s world first DNlite-IVD103 is an urinary ELISA test that can effectively predict progressive eGFR decline (kidney function loss) in a diabetic kidney disease (DKD) patient over the 1-2 years that follow, and perfect for DKD management. DNlite-IVD103 has obtained CE IVD mark, Malaysia MDA and other regulatory-approvals for global market. For more information, please refer to BPM official website: https://www.bpmbiotech.com/products/15.htm

BIOMERIEUX CHINA LIMITED TAIWAN BRANCH

bioMérieux develops and produces in vitro diagnostic solutions (systems, reagents, software and services) for private and hospital laboratories, mainly for the diagnosis of infectious diseases. The results obtained from a patient sample (blood, urine, stool, cerebrospinal fluid, saliva, etc.) provide doctors with information to support their decisions.
bioMérieux has also applied the expertise acquired in the clinical sector to meeting industrial microbiology needs, making it possible to manage contamination risks in agri-food, pharmaceutical and cosmetic products, at each step of the production chain.

BLIRT

BLIRT, Biolab Innovative Research Technologies, is a European Biotech Company that started as a Technical University spin off over 25 years ago to become a well established recombinant enzyme manufacturer in the Life Science Industry. BLIRT manufactures reagents used in nucleic acid based diagnostic tests, such as RT qPCR, RT LAMP, and in situ sequencing, a relatively novel methods used in cancer detection.

BoYen Therapeutics, Inc.

BoYen Therapeutics has a product pipeline with abundance of commercial value. BY-101 is an USFDA designated orphan drug with 7-year period marketing exclusivity. BY-101 is intended for the treatment of acute myeloid leukemia (AML), and will enter Phase 2/3 clinical trials through USFDA 505(b)2 pathway in 2021.BY-102, BY-103 and BYT-3156 are patented drug candidates for the treatment of multiple sclerosis, leukemia, pancreatic cancer, colorectal cancer, lung cancer, breast cancer and other indications.

BoYen Therapeutics, Inc.

BoYen Therapeutics has a product pipeline with abundance of commercial value. BY-101 is an USFDA designated orphan drug with 7-year period marketing exclusivity. BY-101 is intended for the treatment of acute myeloid leukemia (AML), and will enter Phase 2/3 clinical trials through USFDA 505(b)2 pathway in 2021.BY-102, BY-103 and BYT-3156 are patented drug candidates for the treatment of multiple sclerosis, leukemia, pancreatic cancer, colorectal cancer, lung cancer, breast cancer and other indications.

Center for Genomic Medicine, National Cheng Kung University

The advanced maternal age leads to an increased risk of high-risk pregnancy complications, and the increased incidence of low birth weight, chromosomal abnormalities or other congenital defects. Therefore, prenatal genetic diagnosis is important. The main purpose of Center for Genomic Medicine, National Cheng Kung University was to launch high-quality prenatal maternal and child testing. The providing testing includes carrier screening, non-invasive prenatal testing, pre-implantation genetic screening, pre-implantation genetic diagnosis, pregnancy-related gene testing and customized genetic testing. Our goal is \\\"professionalism, excellence, precision and innovation\\\". In this spirit, we provide high-quality genetic technical support, and consultation, hoping to become a new benchmark for prenatal testing and making pre-pregnancy/pre-natal genetic testing more popular, so that every family who wants to have a healthy baby can make their dreams come true.

CHIDON biotechnology co., ltd.

CHIDON® N°9 Agarwood & Herbs Muscle and Joint Pain Relief Body Spray is a environmentally friendly, non-irritating herbal extract. The appearance is transparent and light yellow, and the smell is fresh woody aroma. The extracted raw materials include agarwood, drynaria fortunei and several kinds of herbal materials.

CHIDON® N°9 Agarwood & Herbs Muscle and Joint Pain Relief Body Spray has a unique "instant anti-inflammatory and pain-relieving mechanism" with a refreshing water-based texture and good absorption, which can immediately relieve redness, swelling and discomfort.

CHIDON Biotechnology co., ltd. uses Taiwanese agarwood as raw materials to derive atypical agarwood products with high economic value for pharmaceutical applications. In the future, it will develop products related to anti-coronavirus, anti-onychomycosis and anti-aging of muscles. The open Innovation and cross-industry cooperation model can provide a research and development environment and opportunities in cultivating talents, and jointly develop Chinese herbal medicine extraction and new herbal drugs industries.

Chphilia Bio-Pharmaceutical Ltd

The FREE DUO system has been designed in a one-step analytical system to allow professionals to permit rapid, precise, and accurate oxidation and inflammation detection service. The small size and the functionality of the design mean that FREE DUO can easily use in any area such as a CRO laboratory, wellness center, clinic, hospital, or pharmacy.